Flexion expands mkt for knee OA injectable

Burlington, MA-based Flexion Therapeutics in mid-November announced the full commercial launch of Zilretta (triamcinolone acetonide extended-release injectable suspension), the company’s new therapy for the management of pain associated with osteoarthritis (OA) of the knee. Zilretta, an extended-release, intra-articular corticosteroid injectable, was approved by the US Food and Drug Administration in early October, based on data from a phase 3 randomized double-blind clinical trial involving 484 patients with knee OA pain at 37 centers worldwide; some of these findings were presented in late April at the annual meeting of the Osteoarthritis Research Society International in Las Vegas, NV. The product has been available on a limited basis since October 23

Burlington, MA-based Flexion Therapeutics in mid-November announced the full commercial launch of Zilretta (triamcinolone acetonide extended-release injectable suspension), the company’s new therapy for the management of pain associated with osteoarthritis (OA) of the knee. Zilretta, an extended-release, intra-articular corticosteroid injectable, was approved by the US Food and Drug Administration in early October, based on data from a phase 3 randomized double-blind clinical trial involving 484 patients with knee OA pain at 37 centers worldwide; some of these findings were presented in late April at the annual meeting of the Osteoarthritis Research Society International in Las Vegas, NV. The product has been available on a limited basis since October 23

Excerpt from:
Flexion expands mkt for knee OA injectable